Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. Claims & Support/References for Claims
  4. 338 - Can you advise if published, qualitative studies are acceptable for patient preference claims under the new Code?
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

338 - Can you advise if published, qualitative studies are acceptable for patient preference claims under the new Code?

Scheduled Pinned Locked Moved Claims & Support/References for Claims
1 Posts 1 Posters 480 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Jennifer CarrollJ Offline
    Jennifer CarrollJ Offline
    Jennifer Carroll
    wrote on last edited by Jennifer Carroll
    #1

    I presume you are asking whether it is acceptable to use a survey to assess patient preferences. If I am far off of your intended meaning give me a call. The code change had no impact on this topic. As per before the code change, we can consider this type of presentation when the survey was conducted by a third party receiving unrestricted funding from the sponsor (e.g. sponsor had no influence on the design, the selection of participants, creation of the survey instrument, implementation of the survey, and the analysis of the results). Preference claims must be based on statistically significant results and limited to non-therapeutic aspects of treatment (e.g. "preferred the taste of... " or "preferred the nozzle length of..."). Open claims of "preferred drug X" (i.e. without explicit limitation to non-therapeutic aspects) are not accepted from surveys. Claims of "preferred the efficacy [or safety] of..." are also not accepted based on surveys. Again, call me of this is not what you were looking for.

    1 Reply Last reply
    0
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • Users
    • Groups